Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stefano Rusconi

Showing results (21-30 of 192) with videos related to

Pageof 20
Sort By:
Bioorganic & Medicinal Chemistry Letters|February 23, 2007
Phosph(on)ate as a zinc-binding group in metalloenzyme inhibitors: X-ray crystal structure of the antiviral drug foscarnet complexed to human carbonic anhydrase IClaudia Temperini, Alessio Innocenti, Annalisa Guerri, et al.
The Journal of Antimicrobial Chemotherapy|January 24, 2004
Human cytomegalovirus double resistance in a donor-positive/recipient-negative lung transplant patient with an impaired CD4-mediated specific immune responseFausto Baldanti, Daniele Lilleri, Giulia Campanini, et al.
The Journal of Pediatrics|April 18, 2006
Failure to eradicate HIV despite fully successful HAART initiated in the first days of lifeAlessandra Viganò, Daria Trabattoni, Laura Schneider, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|December 17, 2003
Unusual codon 69 insertions: influence on human immunodeficiency virus type 1 reverse transcriptase drug susceptibilityElisabetta Bulgheroni, Francesco Croce, Paola Citterio, et al.
Health Science Reports|July 22, 2025
Safe Switch to an Oral Two-Drug Regimen Based on Dolutegravir in People With Vertically Acquired HIV-1: An Observational Multicenter StudyGiulia Meraviglia, Anna Sala, Francesco Bassani, et al.
The Journal of Infection|May 24, 2005
Efficacy and tolerability of multiple drug therapy in HIV-infected childrenAlessandra Viganò, Laura Schneider, Vania Giacomet, et al.
Drug Design, Development and Therapy|August 3, 2019
Durability of INI-containing regimens after switching from PI-containing regimens: a single-centre cohort of drug-experienced HIV-infected subjectsAndrea Giacomelli, Alice Ranzani, Letizia Oreni, et al.
Current HIV Research|January 4, 2012
Does GSS still maintain relevance on HAART outcome after the introduction of newest active antiretroviral drugs? 48 weeks resultsMassimiliano Ortu, Paola Vitiello, Fulvio Adorni, et al.
BMC Infectious Diseases|August 8, 2012
Efficacy and safety of a dual boosted protease inhibitor-based regimen, atazanavir and fosamprenavir/ritonavir, against HIV: experience in a pediatric populationStefano Rusconi, Vania Giacomet, Chiara Mameli, et al.
AIDS (London, England)|March 21, 2003
Processivity and drug-dependence of HIV-1 protease: determinants of viral fitness in variants resistant to protease inhibitorsStefano Menzo, Alessia Monachetti, Claudia Balotta, et al.
Pageof 20

Showing results (21-30 of 192) with videos related to

Sort By:
Pageof 20
Bioorganic & Medicinal Chemistry Letters|February 23, 2007
Phosph(on)ate as a zinc-binding group in metalloenzyme inhibitors: X-ray crystal structure of the antiviral drug foscarnet complexed to human carbonic anhydrase IClaudia Temperini, Alessio Innocenti, Annalisa Guerri, et al.
The Journal of Antimicrobial Chemotherapy|January 24, 2004
Human cytomegalovirus double resistance in a donor-positive/recipient-negative lung transplant patient with an impaired CD4-mediated specific immune responseFausto Baldanti, Daniele Lilleri, Giulia Campanini, et al.
The Journal of Pediatrics|April 18, 2006
Failure to eradicate HIV despite fully successful HAART initiated in the first days of lifeAlessandra Viganò, Daria Trabattoni, Laura Schneider, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|December 17, 2003
Unusual codon 69 insertions: influence on human immunodeficiency virus type 1 reverse transcriptase drug susceptibilityElisabetta Bulgheroni, Francesco Croce, Paola Citterio, et al.
Health Science Reports|July 22, 2025
Safe Switch to an Oral Two-Drug Regimen Based on Dolutegravir in People With Vertically Acquired HIV-1: An Observational Multicenter StudyGiulia Meraviglia, Anna Sala, Francesco Bassani, et al.
The Journal of Infection|May 24, 2005
Efficacy and tolerability of multiple drug therapy in HIV-infected childrenAlessandra Viganò, Laura Schneider, Vania Giacomet, et al.
Drug Design, Development and Therapy|August 3, 2019
Durability of INI-containing regimens after switching from PI-containing regimens: a single-centre cohort of drug-experienced HIV-infected subjectsAndrea Giacomelli, Alice Ranzani, Letizia Oreni, et al.
Current HIV Research|January 4, 2012
Does GSS still maintain relevance on HAART outcome after the introduction of newest active antiretroviral drugs? 48 weeks resultsMassimiliano Ortu, Paola Vitiello, Fulvio Adorni, et al.
BMC Infectious Diseases|August 8, 2012
Efficacy and safety of a dual boosted protease inhibitor-based regimen, atazanavir and fosamprenavir/ritonavir, against HIV: experience in a pediatric populationStefano Rusconi, Vania Giacomet, Chiara Mameli, et al.
AIDS (London, England)|March 21, 2003
Processivity and drug-dependence of HIV-1 protease: determinants of viral fitness in variants resistant to protease inhibitorsStefano Menzo, Alessia Monachetti, Claudia Balotta, et al.
Pageof 20